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SUMMARY
The aims of this study were to test the efficacy of immunoglobulin and its Fab and 
Fc fragment in the treatment of experimental autoimmune neuritis (EAN) in Lewis rats, 
to investigate which portion of immunoglobulin is operative in the effect of IVIg, and to 
clarify the possible mechanisms by which immunoglobulin exerts its action in the 
treatment of EAN in the rat.  
EAN was induced by immunization with whole bovine peripheral nerve myelin. 
The immunized rats were randomized into groups, assessed clinically, 
electrophysiologically, and histologically, and intravenously injected with normal saline, 
albumin, human IVIg preparation, purified Fab or Fc fragments. The clinical disease 
severity was evaluated by the daily clinical grading and weight change. The 
electrophysiological studies included the spinal somatosensory evoked potential (S 
wave) and the compound muscle action potential (CMAP). The histopathological 
findings were analysed semiquantitatively. The treatment efficacy was compared 
between the normal saline and albumin groups, albumin and IVIg groups, albumin and 
Fab groups, albumin and Fc groups, Fab and Fc groups, Fab and IVIg groups, and Fc 
and IVIg groups. Methods of myelin isolation, antibody purification, and Western blot 
techniques were also applied. 
The results revealed that treatment with Fc fragment and IVIg administered at the 
onset of signs of disease effectively prevented further progression of disease, shortened 
disease duration, and facilitated recovery from illness as shown in clinical, 
electrophysiological and histological parameters.  
In the study in which the efficacy of the normal saline and albumin was compared, 
no significant difference was noted between these two groups. By day 30, 1 out of 9 rats 
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(11%) in the normal saline group and 2 out of 9 (22%) in the albumin group completely 
recovered from the clinical disease. 
In the study in which the efficacy of the albumin and IVIg was compared, more 
rats completely recovered from the clinical disease in the IVIg group (29% in the 
albumin group and 71% in the IVIg group) by day 30. The animals receiving IVIg 
treatment exhibited significantly lower clinical scores, less prolongation of S wave 
latencies, better maintained S wave amplitudes, less reduction of distal motor 
conduction velocities (MCVs), better maintained distal and proximal amplitudes of 
CMAPs, and lower histological grades.
In the study in which the efficacy of the albumin, Fab fragment, Fc fragment, and 
IVIg was compared, more rats completely recovered from the clinical disease in the Fc 
and IVIg groups (0% in the albumin group, 13% in the Fab group, 50% in the Fc group, 
and 67% in the IVIg group) by day 30. The animals receiving Fc fragment and IVIg 
treatment exhibited significantly lower clinical scores, less prominent weight loss, less 
prolongation of S wave latencies, better maintained S wave amplitudes, less reduction 
of distal MCVs, better maintained distal and proximal CMAP amplitudes, and lower 
histological grades.
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